Skip to main content

How can we help you?

  • Deal or case news
  • 26-05-2021

NautaDutilh as lead counsel assists Keensight Capital with its second direct investment in the Netherlands, being a majority investment in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Symeres is headquartered in the Netherlands, employs over 500 people, many of whom are PhD scientists, operating over six sites spread across the Netherlands, the Czech Republic, Finland and Sweden, along with a business development office in the USA. Management will invest alongside Keensight Capital.

The NautaDutilh team consists of Joost den Engelsman, Sybren de Beurs, Olaf Baks, Quirine van Maanen and Frans Ruijs (Private Equity); Thiemo Kerklaan (Corporate), David Vietor, Jinne van Belle, Eefke Janssen (Finance); Sanne Mesu and Mike Koudenburg (Notarial); Daniel Kuiper and Arjan Koorevaar (Employment); Joost Kloosterman (W&I); Edward Rijnhout and Sjuul Jentjens (Tax), Sasha van Gelder (Insurance), Anne Marie Verschuur and Michelle Slimmen (IP), Terrence Dom and Burcu Yapici (Privacy), Tom de Clerck (Litigation) Eva Reinders and Cyril Christiaans (IT), Ramon Pop (Real Estate), David Wumkes and Maureen van der Wal (Real Estate Notarial), Jolize Lautenbach and Else Bavinck (Regulatory), Mariska Kamta (Due diligence) 

Cookie notice

Our website only uses cookies when you play video content. Video content is streamed from Vimeo. Our website does not use tracking cookies and/or third party cookies when you do not play video content. Please read the privacy/cookie policy for more information.